BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16805911)

  • 1. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
    Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
    J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia.
    Reinhardt D; Diekamp S; Fleischhack G; Corbacioglu C; Jürgens H; Dworzak M; Kaspers G; Creutzig U; Zwaan CM
    Onkologie; 2004 Jun; 27(3):269-72. PubMed ID: 15249716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
    Larson RA; Boogaerts M; Estey E; Karanes C; Stadtmauer EA; Sievers EL; Mineur P; Bennett JM; Berger MS; Eten CB; Munteanu M; Loken MR; Van Dongen JJ; Bernstein ID; Appelbaum FR;
    Leukemia; 2002 Sep; 16(9):1627-36. PubMed ID: 12200674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
    Buckwalter M; Dowell JA; Korth-Bradley J; Gorovits B; Mayer PR
    J Clin Pharmacol; 2004 Aug; 44(8):873-80. PubMed ID: 15286091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Giles F; Estey E; O'Brien S
    Cancer; 2003 Nov; 98(10):2095-104. PubMed ID: 14601078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis.
    Zwaan CM; Reinhardt D; Corbacioglu S; van Wering ER; Bökkerink JP; Tissing WJ; Samuelsson U; Feingold J; Creutzig U; Kaspers GJ
    Blood; 2003 May; 101(10):3868-71. PubMed ID: 12543868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse.
    Sievers EL
    Expert Opin Biol Ther; 2001 Sep; 1(5):893-901. PubMed ID: 11728223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
    Shannon-Dorcy K
    Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia.
    Voutsadakis IA
    Anticancer Drugs; 2002 Aug; 13(7):685-92. PubMed ID: 12187324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
    Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
    Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
    J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
    Cortes J; Tsimberidou AM; Alvarez R; Thomas D; Beran M; Kantarjian H; Estey E; Giles FJ
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):497-500. PubMed ID: 12451477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in antibody therapy for acute myeloid leukemia.
    Tomblyn MR; Tallman MS
    Semin Oncol; 2003 Aug; 30(4):502-8. PubMed ID: 12939719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
    Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
    Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
    Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
    Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg).
    Sievers EL
    Blood Cells Mol Dis; 2003; 31(1):7-10. PubMed ID: 12850477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
    Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
    Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.